Home 
Today's Top Picks 
Top Performers 
Watchlist 
My Robo Portfolios 
ETF Zone 
Help & Tutorial 
Cancel anytime
- Chart
- Upturn Summary
- Highlights
- Revenue
- Valuation
Upturn AI SWOT - About
ACRS 
Aclaris Therapeutics Inc (ACRS)
- BUY Advisory
- SELL Advisory (Profit)
- SELL Advisory (Loss)
- Profit
- Loss
- Pass (Skip investing)
Stock price based on last close (see disclosures)
- ALL
- YEAR
- MONTH
- WEEK
Upturn Advisory Summary
10/17/2025: ACRS (3-star) is currently NOT-A-BUY. Pass it for now.
Upturn Star Rating
Moderate Performance
These Stocks/ETFs, based on Upturn Advisory, typically align with the market average, offering steady but unremarkable returns.
Number of Analysts
6 Analysts rated it
Limited analyst coverage, niche firm, research info may be scarce.
1 Year Target Price $7.86
1 Year Target Price $7.86
| 3 | Strong Buy |
| 2 | Buy |
| 1 | Hold |
| 0 | Sell |
| 0 | Strong Sell |
Analysis of Past Performance
Type Stock | Historic Profit 56.22% | Avg. Invested days 30 | Today’s Advisory PASS |
Upturn Star Rating | Upturn Advisory Performance  2.0 | Stock Returns Performance  3.0 |
| Profits based on simulation | Last Close 10/17/2025 |
Key Highlights
Company Size Small-Cap Stock | Market Capitalization 205.83M USD | Price to earnings Ratio - | 1Y Target Price 7.86 |
Price to earnings Ratio - | 1Y Target Price 7.86 | ||
Volume (30-day avg) 6 | Beta 0.28 | 52 Weeks Range 1.05 - 5.17 | Updated Date 10/19/2025 |
52 Weeks Range 1.05 - 5.17 | Updated Date 10/19/2025 | ||
Dividends yield (FY) - | Basic EPS (TTM) -1.57 |
Analyzing Revenue: Products, Geography and Growth
Revenue by Products
Product revenue - Year on Year
Earnings Date
Report Date - | When - | Estimate - | Actual - |
Profitability
Profit Margin - | Operating Margin (TTM) -951.49% |
Management Effectiveness
Return on Assets (TTM) -20.86% | Return on Equity (TTM) -101.41% |
Valuation
Trailing PE - | Forward PE - | Enterprise Value 80651281 | Price to Sales(TTM) 12.26 |
Enterprise Value 80651281 | Price to Sales(TTM) 12.26 | ||
Enterprise Value to Revenue 4.8 | Enterprise Value to EBITDA 0.28 | Shares Outstanding 108332218 | Shares Floating 72651919 |
Shares Outstanding 108332218 | Shares Floating 72651919 | ||
Percent Insiders 2.69 | Percent Institutions 85.98 |
Upturn AI SWOT
Aclaris Therapeutics Inc
Company Overview
History and Background
Aclaris Therapeutics, Inc. was founded in 2012. It is a biopharmaceutical company focused on developing and commercializing novel treatments for immuno-inflammatory diseases and aesthetic dermatology conditions.
Core Business Areas
- Immuno-inflammatory Diseases: Development and commercialization of therapies targeting immune-mediated and inflammatory dermatological conditions.
- Aesthetic Dermatology: Development and commercialization of aesthetic dermatology products.
Leadership and Structure
Dr. Neal Walker is the CEO. The company has a typical organizational structure for a publicly traded biopharmaceutical company, with departments focused on R&D, clinical development, commercialization, and finance.
Top Products and Market Share
Key Offerings
- Zunlokin: Topical treatment for seborrheic dermatitis, acquired in 2023. Aclaris recently reacquired US rights. Competitors include topical steroids, antifungals, and calcineurin inhibitors from companies like Perrigo (PRGO).
- Vyne: Vyne is Aclaris' lead molecule in the Pipeline which is a novel molecule under investigation for the treatment of various inflammatory and fibrotic conditions. This is in Phase 2 trials. Competitors include drugs in clinical trials from companies such as Horizon Therapeutics.
Market Dynamics
Industry Overview
The pharmaceutical industry, particularly in dermatology, is competitive and driven by innovation. New therapies and technologies are constantly emerging.
Positioning
Aclaris is a player focused on dermatology and immuno-inflammatory diseases with a portfolio of both commercialized and pipeline assets. Their competitive advantage lies in their focus on targeted therapies and their pipeline of novel compounds.
Total Addressable Market (TAM)
The global dermatology market is estimated to be worth hundreds of billions of dollars. Aclaris is targeting specific segments within this market, such as seborrheic dermatitis and other immuno-inflammatory conditions and their positioning with respect to the TAM is based on the assumption that the drugs clear Phase II and Phase III trials.
Upturn SWOT Analysis
Strengths
- Specialized focus in dermatology
- Pipeline of novel compounds
- Experienced management team
- Commercialized products generating revenue
Weaknesses
- Reliance on successful clinical trials
- Relatively small company compared to larger pharmaceutical players
- Dependence on key products
- High R&D expenses
Opportunities
- Expansion into new dermatology indications
- Strategic partnerships and acquisitions
- Increasing awareness of immuno-inflammatory diseases
- Growing demand for aesthetic dermatology products
Threats
- Competition from larger pharmaceutical companies
- Regulatory hurdles and clinical trial failures
- Patent expirations
- Economic downturn affecting healthcare spending
Competitors and Market Share
Key Competitors
- PRGO
- VRX
Competitive Landscape
Aclaris competes with larger pharmaceutical companies in the dermatology space. Their advantage lies in their specialized focus and pipeline, while their disadvantage is their smaller size and resources.
Major Acquisitions
Zunlokin Assets
- Year: 2023
- Acquisition Price (USD millions): 8
- Strategic Rationale: Reacquired US rights to Zunlokin to build commercial derm portfolio.
Growth Trajectory and Initiatives
Historical Growth: Historical growth has been driven by product acquisitions and clinical development milestones.
Future Projections: Future growth depends on the success of their pipeline and expansion into new markets. Analyst estimates should be consulted for specific projections.
Recent Initiatives: Recent initiatives include the acquisition of assets such as Zunlokin and the advancement of their pipeline programs.
Summary
Aclaris Therapeutics is a dermatology-focused company with commercial products and a promising pipeline. Success hinges on clinical trial outcomes and effective commercialization. Competition is strong, but their targeted approach offers potential. Dependence on new product approval is a significant risk, so monitoring regulatory developments is critical.
Peer Comparison
Sources and Disclaimers
Data Sources:
- Company website
- SEC filings
- Analyst reports
Disclaimers:
This analysis is based on publicly available information and should not be considered financial advice. Investment decisions should be made after consulting with a qualified professional.
AI Summarization is directionally correct and might not be accurate.
Summarized information shown could be a few years old and not current.
Fundamental Rating based on AI could be based on old data.
AI-generated summaries may have inaccuracies (hallucinations). Please verify the information before taking action.
About Aclaris Therapeutics Inc
Exchange NASDAQ | Headquaters Wayne, PA, United States | ||
IPO Launch date 2015-10-07 | Co-Founder, CEO & Chairman Dr. Neal S. Walker D.O., M.D. | ||
Sector Healthcare | Industry Biotechnology | Full time employees 61 | Website https://www.aclaristx.com |
Full time employees 61 | Website https://www.aclaristx.com | ||
Aclaris Therapeutics, Inc., a clinical-stage biopharmaceutical company, engages in the development of novel drug candidates for immune-inflammatory diseases in the United States. It operates through two segments, Therapeutics and Contract Research. The Therapeutics segment is involved in identifying and developing therapies to address significant unmet needs for immuno-inflammatory diseases. Its Contract Research segment provides laboratory services. The company also develops ATI-1777, a soft JAK 1/3 inhibitor in Phase 2b trial for the treatment of atopic dermatitis and other dermatologic conditions; Bosakitug (ATI-045), an anti-TSLP monoclonal antibody in Phase 2a trial to treat moderate to severe atopic dermatitis, asthma, chronic rhinosinusitis with nasal polyps, and moderate to severe chronic obstructive pulmonary disease; ATI-2138, an oral covalent inhibitor of ITK and JAK3 inhibitor in Phase 2a trial for the treatment for T cell-mediated autoimmune diseases; Zunsemetinib (ATI-450), a mitogen-activated protein kinase-activated protein kinase 2 inhibitor under Phase 1b/2 trials for the treatment of metastatic breast cancer and pancreatic ductal adenocarcinoma; and ATI-052, a humanized anti-TSLP and anti-IL4R bispecific antibody in preclinical stage to treat various atopic, immunologic, and respiratory diseases, as well as an ITK selective inhibitor candidate for the treatment of autoimmune diseases. Aclaris Therapeutics, Inc. was incorporated in 2012 and is headquartered in Wayne, Pennsylvania.
Note: This website is maintained by Upturn Corporation, which is an investment adviser registered with the U.S. Securities and Exchange Commission. Such registration does not imply a certain level of skill or training. Investing in securities has risks. Past performance is no guarantee of future returns. No assurance is provided as to any particular investment return, and you may lose money using our services. You are strongly advised to consult appropriate counsel before making any investments in companies you learn about through our services. You should obtain appropriate legal, tax, investment, accounting, and other advice that takes into account your investment portfolio and overall financial situation. You are solely responsible for conducting due diligence on a potential investment. We do not affect trades for you. You will select your own broker through which to transact. Investments are not FDIC insured, they are not guaranteed, and they may lose value. Please see the Privacy Policy, Terms of Use, and Disclosure for more information.